Selank Peptide: The Anxiolytic Nootropic Researchers Are Revisiting
Selank is back in the conversation. After a 2026 move back to Category 1 status restored compounding access in the U.S., interest in this decades-old Russian peptide has surged. Known as an anxiolytic nootropic, Selank sits in a different corner of peptide research than the metabolic and recovery compounds that usually dominate headlines. Here's what the research shows.
What is Selank?
Selank is a synthetic heptapeptide (sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, molecular weight ~751.9 Da) derived from tuftsin, a naturally occurring immune-modulating peptide. It was developed in Russia and has decades of published research behind it as an anxiolytic (anti-anxiety) and nootropic (cognition-supporting) agent.
How Selank works
Research points to several overlapping mechanisms. Selank appears to modulate GABA-A receptors, producing anxiolytic effects that some studies compare to classical benzodiazepines — but without the sedation. It also influences serotonin and dopamine turnover and upregulates BDNF and NGF (brain-derived and nerve growth factors) linked to neuroplasticity. Its tuftsin heritage also gives it immunomodulatory activity.
Anxiolytic and cognitive research
In rodent models, Selank reduces anxiety-like behavior and shifts markers of serotonin metabolism. A single intranasal dose has been shown to upregulate BDNF messenger RNA in the hippocampus within hours, alongside broad changes in genes tied to plasticity and inflammation. That dual profile — rapid calming plus longer-term neurotrophic signaling — is what makes it interesting to researchers.
Intranasal delivery and timing
Selank is most often studied via intranasal administration, with cerebrospinal-fluid concentrations peaking roughly 30 minutes after dosing. Published Russian protocols typically use a single morning dose or split doses through the day; the GABAergic calming effect appears within minutes, while BDNF-mediated changes develop over days to weeks.
2026 regulatory note
In February 2026, Selank was moved back to Category 1, restoring legal compounding access in the U.S. and renewing research attention on a compound with a long international track record.
Handling and storage
Selank is supplied as a lyophilized powder and reconstituted before use. See our research guides for general handling and storage practices.
Research use only. This article is educational and is not medical advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.